From The Editor

  1. New Leadership At The Cancer Research Institute 9/27/2024

    Alicia Zhou, Ph.D., the incoming CEO at the Cancer Research Institute, talks about her plans and approach to moving a 70-year old cancer research nonprofit into the future.

  2. A Systems Approach To Parkinson's Disease 8/30/2024

    New research into Parkinson's disease is strengthening the connection between an unhealthy gut and brain disorders.

  3. GLP-1 Drugs Driving Big Budget Impact: PwC's Medical Cost Trend 2025 8/1/2024

    PwC's Medical Cost Trend: Behind The Numbers 2025 report offers details on the key 'inflators' and 'deflators' impacting medical spending next year. The key inflator? You guessed it, weight loss drugs.

  4. Reading The Room In Oncology Drug Development 7/11/2024

    Oral conversations with the FDA about trial design and protocol can lead to questions, and answers, that help drug developers avoid costly surprises and misunderstandings.

  5. Ten Years In, Project Data Sphere Is Snowballing 6/21/2024

    Project Data Sphere, an open access data sharing initiative, is expanding into closed access preclinical research and developing AI models that can benefit drug developers.

  6. Drug Discovery And Development, Powered By Physician Intelligence 5/15/2024

    For Nuvalent CEO James Porter, physician intelligence is more important than artificial intelligence in discovering and developing new therapies that tackle key unmet needs among cancer patients.

  7. Why Fusion Pharma Is The Latest Billion Dollar Big Pharma Buy In Radiopharmaceuticals 3/22/2024

    AstraZeneca's $2.4 billion acquisition of Fusion Pharma is the third billion dollar radiopharmaceuticals deal in recent months. John Valliant, Fusion's founder and CEO, explains why alpha-emitters are better than beta-emitters, and why radiopharmaceuticals are poised for substantial growth.

  8. A Proactive Approach To 'Unscrupulous’ Patent Practices 3/7/2024

    Terran Biosciences aims to subvert a patent strategy some drugmakers have used to delay the entrance of generic competitors. The company is patenting its own psychedelic salts, polymorphs, and prodrugs, and targeting FDA's 505(b)(2) pathway.

  9. The Good And Bad Of Copromotion 2/26/2024

    Are two minds, or companies, better than one for drug commercialization? It depends on the details, says Eisai's Paul Hawthorne.

  10. Innovation From Animals And Evolution 2/1/2024

    Insights gleaned from a variety of animal species, and a deeper understanding of evolution aided by artificial intelligence, could help bring a new wave of therapies to market.